Secondary end point
tumor
DISEASE, TUMOR, ADVERSE EVENTS, BEST
Nine patients (5 in Arm A (10%) and 4 in Arm B (8%)) had an objective response to treatment (complete response or partial response). No statistically significant difference was found between the two arms. The median response duration was 3.7 months and 2.8 months in Arm A and Arm B, respectively. No difference was demonstrated between the two arms. Concerning best tumor response, only one complete response was observed in Arm A and none in Arm B. Four patients (7.7%) in each arm obtained a partial response and 19 patients (36.5%) and 30 patients (57.7%) had a stable disease, respectively, in Arm A and Arm B. No statistical difference was found in terms of better tumor response (Fisher exact test, Best tumor response*17 patients did not have a radiologic reevaluation incompliance with protocol deadlines and were therefore not included in the best tumor response evaluationOverall survival/secondary end point. Main adverse events grade ≥ 3 (frequency > 10%)No statistically significant difference was found between the two treatment arms